Varghese Inchakalody

Dr. Varghese Inchakalody


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Afsheen RazaAfsheen Raza
Afsheen Raza
AKAbdul Khan
Abdul Khan
VIVarghese Inchakalody
Varghese Inchakalody
SMSarra Mestiri
Sarra Mestiri
ZYZeenath Safira K. M. Yoosuf
Zeenath Safira K. M. Yoosuf
Said DermimeSaid Dermime
Said Dermime
Colorectal cancer (CRC) is one of the most common cancers worldwide. The diagnosis, prognosis and therapeutic monitoring of CRC depends largely on tissue biopsy. However, due to tumor heterogeneity and limitations such as invasiveness, high cost and limited applicability in longitudinal monitoring, liquid biopsy has gathered immense attention in CRC. Liquid biopsy has several advantages over tissue biopsy including ease of sampling, effective monitoring, and longitudinal assessment of treatment dynamics. Furthermore, the importance of liquid biopsy is signified by approval of several liquid biopsy assays by regulatory bodies indicating the powerful approach of liquid biopsy for comprehensive CRC screening, diagnostic and prognostics. Several liquid biopsy biomarkers such as novel components of the microbiome, non-coding RNAs, extracellular vesicles and circulating tumor DNA are extensively being researched for their role in CRC management. Majority of these components have shown promising results on their clinical application in CRC including early detection, observe tumor heterogeneity for treatment and response, prediction of metastases and relapse and detection of minimal residual disease. Therefore, in this review, we aim to provide updated information on various novel liquid biopsy markers such as a) oral microbiota related bacterial network b) gut microbiome-associated serum metabolites c) PIWI-interacting RNAs (piRNAs), microRNA(miRNAs), Long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) and d) circulating tumor DNAs (ctDNA) and circulating tumor cells (CTC) for their role in disease diagnosis, prognosis, treatment monitoring and their applicability for personalized management of CRC.

27 March 2020 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
Afsheen RazaAfsheen Raza
Afsheen Raza
Maysaloun MerhiMaysaloun Merhi
Maysaloun Merhi
VIVarghese Inchakalody
Varghese Inchakalody
RKRoopesh Krishnankutty
Roopesh Krishnankutty
ARAllan Relecom
Allan Relecom
Said DermimeSaid Dermime
Said Dermime
Introduction: Cancer Immunotherapy has recently emerged as a promising and effective modality to treat different malignancies. Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to immune intervention in cancer. NY-ESO-1, a cancer testis antigen is the most immunogenic antigen to date. The promise of NY-ESO-1 as a candidate for specific immune recognition of cancer comes from its restricted expression in normal adult tissue but frequent occurrence in multiple tumors including melanoma and carcinomas of lung, esophageal, liver, gastric, prostrate, ovarian, and bladder. Main body: This review summarizes current knowledge of NY-ESO-1 as efficient biomarker and target of immunotherapy. It also addresses limitations and challenges preventing a robust immune response to NY-ESO-1 expressing cancers, and describes pre-clinical and clinical observations relevant to NY-ESO-1 immunity, holding potential therapeutic relevance for cancer treatment. Conclusion: NY-ESO-1 induces strong immune responses in cancer patients but has limited objective clinical responses to NY-ESO-1 expressing tumors due to effect of competitive negative signaling from immune-checkpoints and immune-suppressive tumor microenvironment. We propose that combination therapy to increase the efficacy of NY-ESO-1 specific immunotherapeutic interventions should be explored to unleash the immune response against NY-ESO-1 expressing tumors.

1 September 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SOSoha Osman
Soha Osman
Afsheen RazaAfsheen Raza
Afsheen Raza
LALobna Al-Zaidan
Lobna Al-Zaidan
VIVarghese Inchakalody
Varghese Inchakalody
Maysaloun MerhiMaysaloun Merhi
Maysaloun Merhi
Said DermimeSaid Dermime
Said Dermime
Tranilast (TRN) or (N-3,4 -dimethoxy cinnamoyl]-anthranilic acid) is an analog of a tryptophan metabolite and is identified mainly as an anti-allergic agent with limited side effects. The anti-cancer effects of tranilast either alone or in combination with chemotherapeutic drugs have been evidenced in several pre-clinical studies. The main mechanism of action of tranilast includes targeting and modulation of various signaling and immune regulatory pathways including Transforming growth factor-beta (TGF-β), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), phosphatidylinositol 3-kinase (PI3K), MAP-Kinase (MAPK), Protein kinase B (‎Akt/PKB), c-Jun N-terminal kinase, modulation of cancer stem cells, etc. Most of these pathways are involved in tumor proliferation, invasion, and metastasis and it is postulated that tranilast, with its low toxicity profile and high anti-carcinogenic abilities, can serve as a potential anti-tumorigenic agent. The main aim of this review is to provide updated information on the anti-cancer effects of tranilast and its significance as a therapeutic agent.

2 January 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
HSHarman Saman
Harman Saman
KMKarama Makni-Maalej
Karama Makni-Maalej
DEDina M. Abo El-Ella
Dina M. Abo El-Ella
MAMaryam Yousef Al-Tamimi
Maryam Yousef Al-Tamimi
MHMohannad Natheef Abu Haweeleh
Mohannad Natheef Abu Haweeleh
Shahab UddinShahab Uddin
Shahab Uddin
Immunotherapy represents a paradigm shift in oncology, rooted in a century of evolving scientific understanding and clinical application. From the pioneering use of Coley’s toxins in the late nineteenth century to the introduction of cytokine-based interventions, the trajectory of immunotherapeutic approaches has paralleled advancements in immunology and molecular biology. This review comprehensively examines the historical development and progressive refinement of immunotherapy for cancer, charting the transition from non-specific immune stimulation to targeted immune modulation. Central to this discussion are the sophisticated mechanisms by which tumour cells evade immune detection and destruction. These include downregulation of antigen presentation machinery, secretion of immunosuppressive cytokines, recruitment of regulatory T cells and myeloid-derived suppressor cells, and exploitation of immune checkpoint pathways, particularly CTLA-4 and PD-1/PD-L1 axes. The advent of immune checkpoint inhibitors has yielded durable clinical responses in diverse malignancies, substantiating their role as foundational agents in cancer therapy. Nonetheless, both primary and acquired resistance to immune checkpoint inhibition remain significant clinical obstacles. Resistance mechanisms are multifactorial, involving tumour-intrinsic genetic alterations, modulation of the tumour microenvironment, and adaptive changes in immune cell phenotypes. Contemporary research endeavors are directed at overcoming these barriers, including the optimization of combinatorial regimens, development of next-generation checkpoint modulators, tumour-specific vaccines, and the integration of adoptive cell therapies. Future directions in cancer immunotherapy are poised to leverage advances in systems biology, genomics, and single-cell technologies to individualize interventions and enhance therapeutic efficacy. Ultimately, a comprehensive delineation of tumour-immune interactions will underpin the next generation of rational, effective, and durable cancer immunotherapies.

21 July 2021
Verified
Book Chapter
Open access
PDF file
Afsheen RazaAfsheen Raza
Afsheen Raza
Maysaloun MerhiMaysaloun Merhi
Maysaloun Merhi
ARAllan Relecom
Allan Relecom
QFQueenie Fernandes
Queenie Fernandes
VIVarghese Inchakalody
Varghese Inchakalody
Said DermimeSaid Dermime
Said Dermime
Immune checkpoint inhibitors (ICIs) have been approved as first or second line therapy in a large group of cancers. However, the observation of potentially long-lasting responses was restricted to limited subset of patients. Efforts have been made to identify predictive factors of response to ICIs in order to select eligible patients and to avoid exposing non-responding patients to treatment side effects. Although several biomarkers have been identified, their predictive potential remains unsatisfactory. One promising emerging approach is to focus on dynamic biomarkers to directly characterize the response and, more importantly, to identify those patients presenting an immune response failure. Several studies have shown a strong correlation between specific circulating immune cell subsets and tumor immune infiltrates. Moreover, liquid biomarkers including soluble immune checkpoint molecules have potential in predicting the modulation of the immune response under immune checkpoint blockade. In this chapter, we will discuss current advances in the study of circulatory and intra-tumoral dynamic biomarkers as predictors of responses to ICIs therapy in cancer.

13 May 2021
Verified
Conference Paper
Open access
VYVeeranna Yempally
Veeranna Yempally
QFQueenie Fernandes
Queenie Fernandes
LALobna Safwan Al_Zaidan
Lobna Safwan Al_Zaidan
VIVarghese Inchakalody
Varghese Inchakalody
Maysaloun MerhiMaysaloun Merhi
Maysaloun Merhi
ABAshfaq Bengali
Ashfaq Bengali
There is significant interest in employing rhenium (Re) based carbonyl compounds as potential anti-cancer therapies. These compounds possess a stable Re(CO)3 core and functional groups on the ligand backbone that are linked to a conjugating moiety to bind different biological molecules of interest (see figure 1). Apart from their cytotoxicity, these compounds also